Lygidakis N J, Bhagat Anand D, Vrachnos P, Grigorakos L
Department of Surgical Oncology, Medical Center Psychiko, Athens, Greece.
Hepatogastroenterology. 2007 Jul-Aug;54(77):1353-8.
BACKGROUND/AIMS: In everyday clinical practice many unfortunate patients present with advanced abdominal malignancies and are referred to a medical oncologist for palliative chemoradiotherapy and very few of them are offered surgical treatment. Many such patients, detected either preoperatively or on exploration, are considered to be inoperable and left to live a short and morbid life. The aim of this study was to assess the feasibility and effect of aggressive surgical management with adjuvant chemotherapy in advanced abdominal malignancies requiring resection of one or more organs along with the primary organ of the disease. We retrospectively analyzed our experience of treating such patients.
A total of 62 patients were included in this study attending the clinic between January 2001 and January 2006. These patients were diagnosed to have advanced abdominal malignancies because of spread of the disease from the organ of origin to either contiguous or noncontiguous abdominal organ(s). The patients with ovarian and uterine (n=18) malignancy underwent resection of colon (5), omentum (18), distal pancreatectomy and splenectomy (2), cystectomy (4), parietal peritoneal excision (9), small bowel excision in various combinations along with radical hysterectomy. Twelve patients with advanced colorectal carcinoma (n=12) along with abdominoperineal excision, anterior resection or colonic resection underwent cystectomy (3), hysterectomy (4), small bowel resection (4), hepatic resection (7) or parietal peritoneal excision (4) in various combinations. A total of 14 patients with gastric and gastroesophageal junction malignancy (n=14) underwent gastrectomy or gastroesophagectomy with omentectomy (14), distal pancreatico-splenectomy (5), hepatic resection (9), transverse colectomy (2) and parietal peritoneal excision (2) due to advanced disease. Patients with pancreatic carcinoma (n=12) underwent Whipple's pancreaticoduodenectomy or distal pancreatectomy with hepatic resection (6), transverse colectomy (1), splenectomy (3), left nephrectomy and adrenalectomy (3), small bowel excision (1) and parietal peritoneal excision (3). Along with excision of nonsolid organ retroperitoneal tumors (n=6) the organs resected were left kidney with adrenal (2), spleen (2) right kidney and adrenal (2), segmental inferior vena cava (1) and colon (2). All patients (except those who died in the early postoperative period) received adjuvant chemotherapy (43) or chemobiologic therapy (12) or radiotherapy.
Out of the total 62 patients who underwent multiorgan resection 7 patients died in the immediate postoperative period due to massive pulmonary embolism (2), cardiorespiratory insufficiency (2) or sepsis (3). Important morbidities seen in the early postoperative period were anastomotic leak (3), hemorrhage (2), pulmonary infection (5), pancreatitis (1), wound infection (4) and urinary tract infection (2). There was 100% postoperative follow-up of the patients. The survival rate was 77% in the first, 56.45% in the second, 47% in the third, 32% in the fourth and 22% at the end of the five-year follow-up.
Aggressive surgical intervention by multiorgan resection and adjuvant chemo or chemobiological therapy is a feasible option in patients with advanced abdominal malignancies with statistically improved survival rate. Furthermore, it helps in getting better response to therapeutic manipulations and improved quality of life of the patients.
背景/目的:在日常临床实践中,许多不幸的患者患有晚期腹部恶性肿瘤,并被转介给肿瘤内科医生进行姑息性放化疗,其中很少有人能接受手术治疗。许多这样的患者,无论是在术前还是术中被发现,都被认为无法手术,只能过着短暂而痛苦的生活。本研究的目的是评估在需要切除一个或多个器官以及疾病原发器官的晚期腹部恶性肿瘤中,积极手术治疗联合辅助化疗的可行性和效果。我们回顾性分析了治疗此类患者的经验。
本研究共纳入2001年1月至2006年1月期间到门诊就诊的62例患者。这些患者因疾病从原发器官扩散至相邻或不相邻的腹部器官而被诊断为晚期腹部恶性肿瘤。患有卵巢和子宫恶性肿瘤的患者(n = 18)接受了结肠切除术(5例)、大网膜切除术(18例)、胰体尾切除术和脾切除术(2例)、膀胱切除术(4例)、壁层腹膜切除术(9例)、小肠切除术(各种组合)以及根治性子宫切除术。12例晚期结直肠癌患者(n = 12)在接受腹会阴联合切除术、前切除术或结肠切除术后,接受了膀胱切除术(3例)、子宫切除术(4例)、小肠切除术(4例)、肝切除术(7例)或壁层腹膜切除术(4例)(各种组合)。14例胃和胃食管交界恶性肿瘤患者(n = 14)因病情进展接受了胃切除术或胃食管切除术加网膜切除术(14例)、胰体尾脾切除术(5例)、肝切除术(9例)、横结肠切除术(2例)和壁层腹膜切除术(2例)。胰腺癌患者(n = 12)接受了Whipple胰十二指肠切除术或胰体尾切除术加肝切除术(6例)、横结肠切除术(1例)、脾切除术(3例)、左肾切除术和肾上腺切除术(3例)、小肠切除术(1例)和壁层腹膜切除术(3例)。除了切除非实体器官的腹膜后肿瘤(n = 6)外,还切除了左肾及肾上腺(2例)、脾(2例)、右肾及肾上腺(2例)、节段性下腔静脉(1例)和结肠(2例)。所有患者(除术后早期死亡者外)均接受了辅助化疗(43例)或化学生物治疗(12例)或放疗。
在接受多器官切除的62例患者中,7例患者在术后早期因大面积肺栓塞(2例)、心肺功能不全(2例)或败血症(3例)死亡。术后早期出现的重要并发症包括吻合口漏(3例)、出血(2例)、肺部感染(5例)、胰腺炎(1例)、伤口感染(4例)和尿路感染(2例)。患者术后随访率为100%。五年随访结束时,第一年生存率为77%,第二年为56.45%,第三年为47%,第四年为32%,第五年为22%。
对于晚期腹部恶性肿瘤患者,通过多器官切除及辅助化疗或化学生物治疗进行积极的手术干预是一种可行的选择,其生存率有统计学意义的提高。此外,它有助于对治疗操作产生更好的反应,并改善患者的生活质量。